A Novel Metabolic Score for Predicting the Acute Exacerbation in Patients with Chronic Obstructive Pulmonary Disease
Ling Peng,Hong You,Mei-yu Xu,Zhou-yu Dong,Min Liu,Wen-jing Jin,Chao Zhou
DOI: https://doi.org/10.2147/COPD.S405547
2023-05-06
International Journal of COPD
Abstract:Ling Peng, 1, 2, &ast Hong You, 2, &ast Mei-yu Xu, 2 Zhou-yu Dong, 2 Min Liu, 2 Wen-jing Jin, 2 Chao Zhou 2 1 Department of Critical Care Medicine, Qiannan Buyi and Miao Autonomous Prefecture People's Hospital, Guizhou, People's Republic of China; 2 Department of Respiratory Medicine, Guangming Traditional Chinese Medicine Hospital of Pudong New Area, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chao Zhou, Department of Respiratory Medicine, Guangming Traditional Chinese Medicine Hospital of Pudong New Area, No. 43 DongMen Street. Pudong new District, Shanghai, 201399, People's Republic of China, Tel +86-21-68019069, Email Background: Chronic obstructive pulmonary disease (COPD) has higher mortality when developing to acute exacerbation (AECOPD); hence, the early intervention of COPD is critical for preventing AECOPD. Exploring the serum metabolites associated with acute exacerbation in patients with COPD will contribute to the early intervention of COPD. Methods: In the study, a non-targeted metabolomics strategy combined with multivariate statistical methods was performed to explore the metabolic profiling of COPD developing acute exacerbation, to screen the potential metabolites associated with AECOPD and to analyze the potential value of these metabolites in predicting the development of COPD. Results: Serum lysine, glutamine, 3-hydroxybutyrate, pyruvate and glutamate levels were significantly higher, while 1-methylhistidine, isoleucine, choline, valine, alanine, histidine and leucine levels were significantly lower in AECOPD patients, compared with stable COPD patients after normalization based on the healthy controls. Moreover, eight metabolic pathways were significantly altered (P< 0.05) in the serum of AECOPD patients compared with the stable COPD population, including purine metabolism, glutamine and glutamate metabolism, arginine biosynthesis, butyrate metabolism, ketone body synthesis and degradation, and linoleic acid metabolism. In addition, the correlation analysis between metabolites and AECOPD patients demonstrated that an M-score based on a weighted sum of concentrations of four metabolites including pyruvate, isoleucine, 1-methylhistidine and glutamine were significantly associated with the acute exacerbation of pulmonary ventilation function in COPD patients. Conclusion: Altogether, the metabolite score based on a weighted sum of concentrations of four serum metabolites was associated with an increased risk of COPD developing acute exacerbation, which will provide a new insight for the understanding of COPD development. Keywords: COPD, AECOPD, acute exacerbation, metabolomics, metabolites Chronic obstructive pulmonary disease (COPD) is a chronic airway inflammatory disease, which seriously affect the patient's exercise tolerance and quality of life; 1,2 meanwhile has a heavy economic burden to the society. 3 According to the data from the World Health Organization, COPD is the third leading cause of death and the fifth disease burden globally in 2020. 4 In China, an overall morbidity of COPD is about 8.2%, suggesting an emergent need for prevention and treatment. 5 COPD is characterized by persistent respiratory symptoms and airflow, usually as a result of high exposure to harmful particles or gases. 6,7 The acute exacerbation of COPD (AECOPD) often leads to clinical death and the aggravation of economic burden in these patients. 8,9 Hence, early diagnosis and intervention are crucial for preventing AECOPD. 10 Previously, FEV1/FVC and FEV1 were used as predicted values to assess the degree of airflow limitation in AECOPD. 11,12 However, in real world, patients with AECOPD can often not complete the pulmonary function test or even though they are reluctant to complete the test, the results are not credible. 13 Given the fact, it is particularly urgent to explore the serum biological indicators to evaluate the development of COPD. In recent years, the development of omics technologies has revolutionized biomedical research, particularly the metabolomics provides a powerful tool for discovering the novel biomarkers in various clinical fields. 14,15 A variety of metabolite panels have been used in screening, assessing and monitoring the disease development and therapeutic efficacy 16,17 and metabolomics-based panels make different studies more comparable and available. 18,19 At present, the application of metabolomics in the field of COPD has made great progress in these years. Recently, a -Abstract Truncated-
respiratory system